Diabetic neuropathic pain: Real world treatment options

Clinical Medicine Insights: Therapeutics

Volumn 4, Issue , 2012, Pages 169-183

  Lindsay, Tammy J ^a   Vitrikas, Kirsten ^a   Temporal, Michael ^a   Herndon, Christopher M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alternative medicine; Anticonvulsants; Antidepressants; Complementary; Diabetes mellitus; Guidelines; Opioids; Painful diabetic peripheral neuropathy; Treatment

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; GABAPENTIN; IMIPRAMINE; MIRTAZAPINE; NARCOTIC ANALGESIC AGENT; NATURAL PRODUCT; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PREGABALIN; PROTRIPTYLINE; TOPIRAMATE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VALPROIC ACID; VASODILATOR AGENT; VENLAFAXINE; VILAZODONE;

AGRANULOCYTOSIS; ALLODYNIA; BEDTIME DOSAGE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EFFECTIVENESS; DIABETIC NEUROPATHY; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FUNCTIONAL ASSESSMENT; GLUCOSE INTOLERANCE; HUMAN; HYPERALGESIA; HYPERTRANSAMINASEMIA; HYPONATREMIA; HYPOTENSION; INSOMNIA; INSULIN RESISTANCE; LIVER TOXICITY; LOW DRUG DOSE; NEUROPATHIC PAIN; NONHUMAN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PAINFUL DIABETIC PERIPHERAL NEUROPATHY; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; QUALITY OF LIFE; REVIEW; SEDATION; SIDE EFFECT; SLEEP QUALITY; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TERATOGENICITY; TREATMENT DURATION; TREATMENT PLANNING; TRIGEMINUS NEURALGIA; WEIGHT GAIN;

EID: 84864049411     PISSN: 1179559X     EISSN: 1179559X     Source Type: Journal    
DOI: 10.4137/CMT.S7266     Document Type: Review

References (113)

1. Haanpaa M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. Jan 2011;152(1):14-27.
2. Rayman G, Baker NR, Krishnan ST. Glyceryl trinitrate patches as an alternative to isosorbide dinitrate spray in the treatment of chronic painful diabetic neuropathy. Diabetes Care. Sep 2003;26(9):2697-8.
3. Yuen KC, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care. Oct 2002;25(10):1699-703.
4. Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American academy of neurology, the American association of neuromuscular and electrodiagnostic medicine, and the American scademy of physical medicine and rehabilitation. Neurology. May 17, 2011;76(20):1758-65.
5. Berger A, Dukes E, Edelsberg J, Stacey B, Oster G. Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy. Clin J Pain. Mar-Apr 2007;23(3):251-8.
6. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage. Dec 2000;20(6):449-58.
7. Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry. Mar 2001;13(1):31-41.
8. Artigas F, Nutt DJ, Shelton R. Mechanism of action of antidepressants. Psychopharmacol Bull. Summer 2002;36 Suppl 2:123-32.
9. Bourin M, Chenu F, Hascoet M. The role of sodium channels in the mechanism of action of antidepressants and mood stabilizers. Curr Drug Targets. Nov 2009;10(11):1052-60.
10. Cayley WE Jr. Antidepressants for the treatment of neuropathic pain. Am Fam Physician. Jun 1 2006;73(11):1933-4.
11. Chan HN, Fam J, Ng BY. Use of antidepressants in the treatment of chronic pain. Ann Acad Med Singapore. Nov 2009;38(11):974-9.
12. Rudorfer MV, Potter WZ. Metabolism of tricyclic antidepressants. Cell Mol Neurobiol. Jun 1999;19(3):373-409.
13. Heymann RE, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clin Exp Rheumatol. Nov-Dec 2001;19(6):697-702.
14. Miljkovic B, Pokrajac M, Timotijevic I, Varagic V. Clinical response and plasma concentrations of amitriptyline and its metabolite-nortriptyline in depressive patients. Eur J Drug Metab Pharmacokinet. Jul-Sep 1996; 21(3):251-5.
15. Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology. Oct 1998;51(4):1166-71.
16. Gormsen L, Rosenberg R, Bach FW, Jensen TS. Depression, anxiety, healthrelated quality of life and pain in patients with chronic fibromyalgia and neuropathic pain. Eur J Pain. Feb 2010;14(2):127. e121-8.
17. Jordan KD, Okifuji A. Anxiety disorders: differential diagnosis and their relationship to chronic pain. J Pain Palliat Care Pharmacother. 2011;25(3): 231-45.
18. Barbui C, Hotopf M, Freemantle N, et al. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev. 2000(4):CD002791.
19. Furukawa T, McGuire H, Barbui C. Low dosage tricyclic antidepressants for depression. Cochrane Database Syst Rev. 2003(3):CD003197.
20. Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics. Sep-Oct 2004;45(5): 371-7.
21. Holliday SM, Plosker GL. Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy. Drugs Aging. May-Jun 1993;3(3):278-99.
22. Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. Aug 1990;42(2):135-44.
23. Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. Nov 1992;52(5): 547-52.
24. Guldiken S, Guldiken B, Arikan E, Altun Ugur B, Kara M, Tugrul A. Complete relief of pain in acute painful diabetic neuropathy of rapid glycaemic control (insulin neuritis) with venlafaxine HCL. Diabetes Nutr Metab. Aug 2004;17(4):247-9.
25. Kadiroglu AK, Sit D, Kayabasi H, Tuzcu AK, Tasdemir N, Yilmaz ME. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications. Jul-Aug 2008;22(4):241-5.
26. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebocontrolled study. Pain. Aug 2004;110(3):697-706.
27. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev. 2009(4):CD007115.
28. Lee SI, Keltner NL. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine. Perspect Psychiatr Care. May 2006;42(2):144-8.
29. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs. Feb 1995;49(2): 280-94.
30. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. Oct 1998;59(10):502-8.
31. McIntyre RS, Panjwani ZD, Nguyen HT, et al. The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol. Mar 2008;4(3): 281-5.
32. Khurana RC. Treatment of painful diabetic neuropathy with trazodone. Jama. Sep 16, 1983;250(11):1392.
33. Wilson RC. The use of low-dose trazodone in the treatment of painful diabetic neuropathy. J Am Podiatr Med Assoc. Sep 1999;89(9): 468-71.
34. Semenchuk MR, Davis B. Efficacy of sustained-release bupropion in neuropathic pain: an open-label study. Clin J Pain. Mar 2000;16(1):6-11.
35. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology. Nov 13, 2001;57(9):1583-8.
36. Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother. Sep 2006;6(9):1249-65.
37. Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol. Oct 2006;26(5):482-8.
38. Davis J, Barkin RL. Clinical pharmacology of mirtazapine: revisited. Am Fam Physician. Sep 15, 1999;60(4):1101.
39. Aranda-Michel J, Koehler A, Bejarano PA, et al. Nefazodone-induced liver failure: report of three cases. Ann Intern Med. Feb 16, 1999;130(4 Pt 1): 285-8.
40. Goodnick PJ, Breakstone K, Kumar A, Freund B, DeVane CL. Nefazodone in diabetic neuropathy: response and biology. Psychosom Med. Jul-Aug 2000;62(4):599-600.
41. Khan A. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs. Nov 2009;18(11):1753-64.
42. Middleton DJ, Cameron IM, Reid IC. Continuity and monitoring of antidepressant therapy in a primary care setting. Qual Prim Care. 2011;19(2): 109-13.
43. Mula M. Anticonvulsants-antidepressants pharmacokinetic drug interactions: the role of the CYP450 system in psychopharmacology. Curr Drug Metab. Oct 2008;9(8):730-7.
44. Sabers A, Gram L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs. Jul 2000;60(1):23-33.
45. Gill D, Derry S, Wiffen PJ, Moore RA. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011(10):CD009183.
46. Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute and chronic pain in adults. Cochrane Database Syst Rev. 2011(1):CD005451.
47. Onady AA, Calabrese JR. Carbamazepine auto-and hetero-induction complicating clinical care. J Clin Psychopharmacol. Oct 1989;9(5):387-8.
48. Pynnonen S, Frey H, Sillanpaa M. The auto-induction of carbamazepine during long-term therapy. Int J Clin Pharmacol Ther Toxicol. Jun 1980;18(6):247-52.
49. Wiffen PJ, Derry S, Moore RA. Lamotrigine for acute and chronic pain. Cochrane Database of Systematic Reviews (Online). 2011(2):CD006044.
50. Holbech JV, Otto M, Bach FW, Jensen TS, Sindrup SH. The anticonvulsant levetiracetam for the treatment of pain in polyneuropathy: a randomized, placebo-controlled, cross-over trial. European Journal of Pain (London, England). Jul 2011;15(6):608-14.
51. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011(3):CD007938.
52. Wiffen PJ, McQuay HJ, Edwards J, Moore RA. WITHDRAWN: Gabapentin for acute and chronic pain. Cochrane Database Syst Rev. 2011(3): CD005452.
53. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009(3): CD007076.
54. Hoppe C, Rademacher M, Hoffmann JM, Schmidt D, Elger CE. Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients? Seizure. Jun 2008;17(4):327-32.
55. Page RL, 2nd, Cantu M, Lindenfeld J, Hergott LJ, Lowes BD. Possible heart failure exacerbation associated with pregabalin: case discussion and literature review. J Cardiovasc Med (Hagerstown). Sep 2008;9(9):922-5.
56. Ifuku M, Iseki M, Hidaka I, Morita Y, Komatus S, Inada E. Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. Pain Med. Jul 2011;12(7):1112-6.
57. Toth C. Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Med. Mar 2010;11(3): 456-65.
58. Guay DR. Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain. Am J Geriatr Pharmacother. Sep 2003;1(1):18-37.
59. Shank RP, Smith-Swintosky VL, Maryanoff BE. Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. J Enzyme Inhib Med Chem. Apr 2008; 23(2):271-6.
60. Donofrio PD, Raskin P, Rosenthal NR, et al. Safety and effectiveness of topiramate for the management of painful diabetic peripheral neuropathy in an open-label extension study. Clin Ther. Sep 2005;27(9):1420-31.
61. Raskin P, Donofrio PD, Rosenthal NR, et al. Topiramate vs. placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology. Sep 14 2004;63(5):865-73.
62. Atli A, Dogra S. Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. Pain Med. May-Jun 2005;6(3):225-34.
63. Carroll DG, Kline KM, Malnar KF. Role of topiramate for the treatment of painful diabetic peripheral neuropathy. Pharmacotherapy. Sep 2004;24(9): 1186-93.
64. Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: a review. Epilepsy Res. Aug 2011;95(3): 189-99.
65. Kramer CK, Leitao CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev. May 2011;12(5):e338-47.
66. Lim J, Ko YH, Joe SH, Han C, Lee MS, Yang J. Zonisamide produces weight loss in psychotropic drug-treated psychiatric outpatients. Prog Neuropsychopharmacol Biol Psychiatry. Dec 1, 2011;35(8): 1918-21.
67. Singh SK, Thapa SS, Badhu BP. Topiramate induced bilateral angle-closure glaucoma. Kathmandu Univ Med J (KUMJ). Apr-Jun 2007;5(2):234-6.
68. Chung SS, Kerls S, Hammer A, Kustra R. Cognitive effects of lamotrigine versus topiramate as adjunctive therapy in older adults with epilepsy. Neurol Int. 2009;1(1):e6.
69. Lin LC, Lai PC, Yang SF, Yang RC. Oxcarbazepine-induced Stevens-Johnson syndrome: a case report. Kaohsiung J Med Sci. Feb 2009;25(2): 82-6.
70. Kakkar AK, Rehan HS, Unni KE, Gupta NK, Chopra D, Kataria D. Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study. Eur Psychiatry. Apr 2009;24(3):178-82.
71. Rauck RL, Shaibani A, Biton V, Simpson J, Koch B. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain. Feb 2007;23(2):150-8.
72. Wymer JP, Simpson J, Sen D, Bongardt S. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain. Jun 2009;25(5):376-85.
73. Ziegler D, Hidvegi T, Gurieva I, et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care. Apr 2010;33(4):839-41.
74. Shaibani A, Fares S, Selam JL, et al. Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain. Aug 2009;10(8):818-28.
75. Hearn L, Derry S, Moore RA. Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;2:CD009318.
76. Cetinkaya Y, Kurtulmus YS, Tutkavul K, Tireli H. The effect of oxcarbazepine on bone metabolism. Acta Neurol Scand. Sep 2009;120(3):170-5.
77. El-Hajj Fuleihan G, Dib L, Yamout B, Sawaya R, Mikati MA. Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone. Jul 2008;43(1):149-55.
78. Ensrud KE, Walczak TS, Blackwell TL, Ensrud ER, Barrett-Connor E, Orwoll ES. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology. Sep 2, 2008;71(10):723-30.
79. Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. Cochrane Database Syst Rev. 2008(4):CD004844.
80. Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. J Pain Symptom Manage. Apr 2010;39(4):768-78.
81. Torigoe K, Nakahara K, Rahmadi M, et al. Usefulness of Olanzapine as an Adjunct to Opioid Treatment and for the Treatment of Neuropathic Pain. Anesthesiology. Nov 28, 2011.
82. Lauretti GR. Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. May-Jun 2008;58(3):280-6.
83. Ebell MH. Systemic lidocaine or mexiletine for neuropathic pain. Am Fam Physician. Jul 1, 2006;74(1):79.
84. Jarvis B, Coukell AJ. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs. Oct 1998;56(4):691-707.
85. Marmura MJ. Intravenous lidocaine and mexiletine in the management of trigeminal autonomic cephalalgias. Curr Pain Headache Rep. Apr 14(2): 145-50.
86. Ho KY, Huh BK, White WD, Yeh CC, Miller EJ. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin J Pain. Jan 2008;24(1):51-5.
87. Jensen MP. Introduction: chronic pain studies of the lidocaine patch 5% using the Neuropathic Pain Scale. Current Medical Research and Opinion. 2004;20 Suppl 2:S1-4.
88. White WT, Patel N, Drass M, Nalamachu S. Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Medicine Malden, Mass. Dec 2003;4(4):321-30.
89. Yao P, Meng LX, Ma JM, et al. Sustained-Release Oxycodone Tablets for Moderate to Severe Painful Diabetic Peripheral Neuropathy: A Multicenter, Open-Labeled, Postmarketing Clinical Observation. Pain Med. Nov 14, 2011.
90. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. Jun 1998;50(6):1842-6.
91. Moulin D. Tramadol for the treatment of the pain of diabetic neuropathy. Neurology. Apr 12, 1999;52(6):1301.
92. Hays L, Reid C, Doran M, Geary K. Use of methadone for the treatment of diabetic neuropathy. Diabetes Care. Feb 2005;28(2):485-7.
93. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. Jan;27(1):151-62.
94. Macintyre PE, Loadsman JA, Scott DA. Opioids, ventilation and acute pain management. Anaesth Intensive Care. Jul 2011;39(4):545-58.
95. Klein AW. The therapeutic potential of botulinum toxin. Dermatol Surg. Mar 2004;30(3):452-5.
96. Jabbari B, Machado D. Treatment of refractory pain with botulinum toxins-an evidence-based review. Pain Med. Nov 2011;12(11): 1594-606.
97. Albers JW, Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. May 2010;33(5):1090-6.
98. Ang Cynthia D, Alviar Maria Jenelyn M, Dans Antonio L, et al. Vitamin B for treating peripheral neuropathy. Cochrane Database of Systematic Reviews. 2008; (3). http://www.mrw.interscience.wiley.com/ cochrane/clsysrev/articles/CD004573/frame.html.
99. Murad MH, Smith SA. Review: TCAs, anticonvulsants, opioids, and capsaicin cream are effective for diabetic neuropathy. Evid Based Med. Feb 2008;13(1):21.
100. Biesbroeck R, Bril V, Hollander P, et al. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther. Mar-Apr 1995;12(2):111-20.
101. Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. Sep 2011;34(9):2054-60.
102. Leonard DR, Farooqi MH, Myers S. Restoration of sensation, reduced pain, and improved balance in subjects with diabetic peripheral neuropathy: a double-blind, randomized, placebo-controlled study with monochromatic near-infrared treatment. Diabetes Care. Jan 2004;27(1): 168-72.
103. Harkless LB, DeLellis S, Carnegie DH, Burke TJ. Improved foot sensitivity and pain reduction in patients with peripheral neuropathy after treatment with monochromatic infrared photo energy--MIRE. J Diabetes Complications. Mar-Apr 2006;20(2):81-7.
104. Lavery LA, Murdoch DP, Williams J, Lavery DC. Does anodyne light therapy improve peripheral neuropathy in diabetes? A double-blind, sham-controlled, randomized trial to evaluate monochromatic infrared photoenergy. Diabetes Care. Feb 2008;31(2):316-21.
105. Nawfar SA, Yacob NB. Effects of monochromatic infrared energy therapy on diabetic feet with peripheral sensory neuropathy: a randomised controlled trial. Singapore Med J. Sep 2011;52(9):669-72.
106. Chen W, Zhang Y, Liu Jian P. Chinese herbal medicine for diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews. 2011(6). http:// www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/ CD007796/ frame.html.
107. Tong Y, Guo H, Han B. Fifteen-day acupuncture treatment relieves diabetic peripheral neuropathy. J Acupunct Meridian Stud. Jun 2010;3(2): 95-103.
108. Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R. Apr 2011;3(4):345-52, 352. e341-21.
109. Bril V, England JD, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine and Rehabilitation. Muscle Nerve. Jun 2011;43(6):910-7.
110. Tan T, Barry P, Reken S, Baker M. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ. 2010;340:c1079.
111. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. Sep 2010;17(9):e1113-1188.
112. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. Oct 2009;122(10 Suppl):S22-32.
113. Boulton AJ, Malik RA. Diabetic neuropathy. Med Clin North Am. Jul 1998; 82(4):909-29.